spacer
home > ebr > winter 2003 > will demand exceed supply for biopharmaceutical manufacturing?
PUBLICATIONS
European Biopharmaceutical Review

Will Demand Exceed Supply for Biopharmaceutical Manufacturing?

Manufacturing capacities have increasingly become cause for much speculation; many biopharmaceutical market participants consider this to be a crucial issue which will make or break the industry's progression. Once a new drug is discovered and clinical trials are conducted and approved by the drug approval authorities, the actual task of manufacture for commercial application begins. Construction of manufacturing facilities is not an easy task and requires anywhere between three to five years with a typical investment of around US$500 million. In the current economic situation, where raising capital is a difficult undertaking, building biopharmaceutical manufacturing reactors is not easy.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Raju Adhikari, Mbiochem, Dphil, Research Analyst at Frost and Sullivan, Europe

Raju Adhikari, Mbiochem, DPhil is a Research Analyst at Frost and Sullivan, Europe. Since joining Frost and Sullivan, Raju has been involved in the research, analysis and production of market studies in the biotechnology field. His experience in the biotechnology sector comes from three years spent working at Everest Biotechnology Ltd, an emerging antibody company. As Chief Scientific Officer, his role involved Product Management, Business Development, Quality Control and Marketing/PR. Raju graduated with a First Class Masters degree from the University of Oxford. He received his doctorate, also from the University of Oxford, in the field of Immunology and has published several papers in scientific journals.

spacer
Raju Adhikari
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Destiny Pharma appoints MedPharm to develop new XF-platform drug formulations

Destiny Pharma, a clinical stage biotechnology company focused on the development of novel antimicrobial drugs, is pleased to announce that it has appointed MedPharm as its expert partner to develop new topical formulations of the Company’s novel XF-platform compounds. These new treatments for dermal and ocular infections are part of its second clinical programme to address the global problem of anti-microbial resistance (AMR). MedPharm is a world leading contract provider of topical and transdermal product design and formulation development services using sophisticated in vitro models to de-risk development programmes.
More info >>

White Papers

Blockbuster Drugs Need Blockbuster Components

West Pharmaceutical Services, Inc.

Many of the world’s blockbuster drugs are now delivered via a prefilled syringe system or auto-injector. To ensure patient safety, pharmaceutical manufacturers need high-quality components that feature reduced particulates and ensure consistency of delivery while fitting the changing needs of higher-volume delivery systems.
More info >>

 
Industry Events

SAPHEX 2019

23-24 October 2019, GALLAGHER CONVENTION CENTRE, 10 RICHARDS DRIVE, HALFWAY HOUSE, MIDRAND, 1685, SOUTH AFRICA

SAPHEX 2019 will be held on the 23rd-24th October at the Gallagher Convention Centre, Johannesburg, South Africa.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement